



IGPA CALLS FOR EQUAL STATUS FOR GENERICS INDUSTRY

AT GLOBAL PHARMACEUTICAL STANDARDS ORGANIZATION MEETING

Generics are more than 50% of global prescriptions, equal participation in all aspects of management and standards-setting in International Conference on Harmonization best serves public health.

LISBON, PORTUGAL (November 10, 2014) —

Statement by David Gaugh, International Generic Pharmaceutical Alliance (IGPA) Management Committee Representative:

“The International Generic Pharmaceutical Alliance (IGPA) met yesterday with the Steering Committee of the International Conference on Harmonization (ICH) to present details on the IGPA request to gain ICH Executive Board membership. IGPA member associations represent companies making more than half of prescriptions worldwide. IGPA also represents companies that have moved into developing and manufacturing biosimilar medicines.

Having participated in ICH since 1997, we have the utmost respect for ICH and what it has accomplished. What we seek now is a seat on the ICH Executive Board (formerly the Steering Committee). The Executive Board will perform the executive function for ICH. The ICH executive function has historically been performed by global regulators and brand pharmaceutical industry representatives, without the beneficial input that the generic industry can provide. Even administrative decisions can significantly impact the outcome of a proceeding. We believe the generic industry should be a full part of those discussions and decisions.

If IGPA is permitted to join the ICH Executive Board, it would fully participate in all decisions relating to ICH management and harmonization of global drug quality, safety, and efficacy standards. We would like to be full participants so that we can help ICH to represent public health in the 21st century.

We were grateful for the opportunity to address the Steering Committee. We are optimistic about what we heard at today’s meeting, and we look forward to contributing our scientific expertise to all important ICH discussions as a member of the ICH Executive Board.”



Canadian Generic Pharmaceutical Association
4120 Yonge Street
Suite 409
Toronto, Ontario
M2P 2B8, Canada
T: + 1 416 223 2333
www.canadiangenerics.ca



European Generic Medicines Association
Rue d'Arlon 50
B-1000 Brussels, Belgium
T: +32 2 736 84 11
www.egagenerics.com



Generic Pharmaceutical Association
777 6th Street, NW
Suite 510
Washington, DC 20001
T: +1 202 249 7100
www.gphaonline.org



The Jordanian Association of Pharmaceutical Manufacturers
Khaldi, Villa No. 1
Yazan Aranki Street
P.O. Box 5382
Amman, 11953 Jordan
T: +962 6 5413114
www.japm.com



Japan Generic Medicines Association
3-3-4 Nihonbashi-honcho
Chuo-ku, Tokyo
103-0023 Japan
T: +81 3 3279 1890
www.jga.gr.jp



National Association of Pharmaceutical Manufacturers
Ground Floor
1342 Howick Mews
Waterfall Park,
Bekker RD, Midrand
P.O. Box 32361, 1684
Kyalami, South Africa
T: +27 11 312 6966
www.napm.co.za



For a link to IGPA's slide presentation, please see

http://www.igpagenerics.com/doc/ICH_Steering_Committee_Lisbon_09_11_2014.pdf

For any questions please contact www.igpagenerics.com

##

About IGPA: The International Generic Pharmaceutical Alliance was born as an international network of generic medicines associations, committed to promoting generic medicines and exchanging information worldwide. The IGPA was founded in March 1997 and consists of the following associations:

- *Canadian Generic Pharmaceutical Association (CGPA-Canada)*
- *European Generic medicines Association (EGA-Europe)*
- *US Generic Pharmaceutical Association (GPhA-USA)*
- *Jordanian Association of Pharmaceutical Manufacturers (JAPM-Jordanian)*
- *Japan Generic Medicines Association (JGA-Japan)*
- *National Association of Pharmaceutical Manufacturers (NAPM-South Africa)*
- *In addition, generic medicines associations from Australia, Brazil, Mexico and Taiwan are associate members*